DaVita stands as one of the largest providers of kidney care and dialysis services in the United States. Its quarterly updates give a clear window into treatment volumes, reimbursement trends, and cost pressures affecting the outpatient healthcare space. Most revenue comes from per-treatment payments under Medicare, Medicaid, and commercial insurance. That makes it important to track how payor mix, volume growth, and patient care costs affect overall profitability. Heading into this report, DVA had topped consensus EPS estimates in each of the prior four quarters, so the bar was set high and guidance along with cash flow trends carried extra weight.
For the period ended September 30, 2026, consolidated revenue reached roughly $3.58 billion, up 4.6% from the year-ago quarter and above the consensus mark near $3.52 billion. Adjusted diluted EPS of $3.82 cleared analyst forecasts that ranged from about $3.55 to $3.78. GAAP diluted EPS landed at $3.40 after a $62 million non-cash goodwill and other asset impairment charge tied to the China operations.
Operating metrics showed modest progress. U.S. dialysis treatments totaled about 7.33 million, with normalized non-acquired treatment growth of 0.4% year over year. Revenue per treatment climbed to $415.25 from $405.15, while patient care costs per treatment rose to $280.22 from $271.23, reflecting higher compensation and supply expenses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cash flow came under pressure, with operating cash flow falling to $519 million from $842 million and free cash flow dropping to $276 million from $604 million. Management held full-year adjusted diluted EPS guidance steady at $14.30 to $15.20, a midpoint of $14.75 that sat a bit below some consensus estimates. The company repurchased 0.6 million shares for roughly $111 million in the quarter.
Even with the revenue and adjusted EPS beats, shares of DVA moved lower in after-hours trading. Attention shifted to the unchanged guidance range and the weaker cash flow numbers. The midpoint of the EPS outlook disappointed some investors who had expected a more noticeable increase. The impairment charge and cash flow decline added to the cautious tone. This reaction highlights that earnings quality and forward visibility often outweigh a single quarter’s headline surprise. Sentiment before the report had been positive given the stock’s year-to-date gains, which may have lifted expectations and contributed to the post-release move.
Looking ahead, the focus will be on whether modest treatment volume growth can translate into stronger free cash flow. Rising patient care costs per treatment could pressure margins if wages, supplies, or insurance expenses continue to climb, even as revenue per treatment improves. Reimbursement trends remain central, given the heavy reliance on Medicare, Medicaid, and commercial rates. Keeping guidance unchanged signals a measured outlook where cost control and volume trends balance reimbursement uncertainty. The China business and its impairment charge deserve ongoing monitoring because international operations can add volatility. Share repurchases will also stay in view as buybacks have supported EPS growth historically. The main questions now center on cash flow recovery, sustainable treatment growth, and whether management can raise the outlook in coming quarters.
When analyzing results like these, I often turn to Tickeron’s AI Trend Prediction Engine to gauge how broader market signals align with company-specific data. It provides an additional layer of perspective on potential price movement without replacing traditional fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DVA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 26 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 65%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DVA as a result. In 51 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
DVA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DVA crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
The 50-day moving average for DVA moved below the 200-day moving average on November 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
The Aroon Indicator for DVA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DVA's RSI Indicator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 245 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
DVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. DVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.956) is normal, around the industry mean (204.532). P/E Ratio (15.431) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.436) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement